Aristotle University Of Thessaloniki (AUTH)
Μελέτη κόστους και ποιότητας ζωής ασθενών με αγκυλοποιητική σπονδυλοαρθρίτιδα υπό βιολογικές θεραπείες στην Ελλάδα
Abstract
dc:descriptionThe concept of Axial Spa was realized in 2009 by ASAS. It was a result of the need to early recognize and diagnose patients with Ankylosing Spondylitis (AS), which were until then diagnosed according to imaging and clinical criteria of 1984 New York. The use of MRI and the understanding of the role of HLA-B27 contributed to the identification of patients with all the clinical features of AS but without definite radiographic changes. This subgroup of patients was labeled as non-radiographic Axial Spa in contrast to AS which has the characteristic radiographic changes according to New York criteria. Both entities, AS and non-radiographic Axial Spa, are included in Axial Spa, which is a part of a larger family of diseases, the Spondyloarthropathies. As the disease starts usually between the second and third decade of life and has a chronic progression, the impact on quality of life, the ability to perform paid work, and health resources is significant. From a socio-economic point of view, it is important to use therapies that prevent or slow down the progression of the disease, thus avoiding the high economic costs associated with it, the reduction of productivity and the deterioration of the quality of life. The introduction of biological therapies in the treatment of inflammatory diseases has brought impressive results in the course of the disease. However, their increased financial costs compared to conventional treatments question the use of these drugs and therefore pharmacoeconomic studies are needed to prove the effectiveness of such interventions. In this study, we estimated the cost of illness, quality of life and workability among patients with axial Spa treated with biologic agents in Greece. The average annual total cost from the payer’s perspective amounts to € 8,504. The largest part of the cost (~ 87%) is due to the cost of obtaining the biological treatment and then a very significant contribution to the total cost has the administration cost of drugs (11%). From the patient's perspective, the average annual total cost is € 939. Most of the cost (~ 52%) corresponds to the indirect cost, ie the loss of productivity caused by the inability of patients to work as a result of their condition or because relatives have to take a leave to care for them. A significant contribution to the total cost has also the direct non-medical costs (46%), which include the costs of transporting patients to and from the hospital, and home adjustments.Regarding work productivity, an improvement of disease activity as measured with BASDAI is associated with an increase in performance at work. In our study, the mean BASDAI of the patients starting biological treatment decreased from 5.74 to 3.2 after 52 weeks while work productivity loss decreased from 30% to 20% accordingly. Similarly, absenteeism and presenteeism also decreased from 9% and 32% to 5% and 23%. The same positive effect on the work productivity of patients with AS was documented by improving their quality of life. The data collected from the HAQ questionnaires showed a reduction of the scale from 1.13 at baseline to 0.75 at the end of the follow-up period. The HAQ and BASDAI scores according to our regression analysis were the factors with the most important predictive value for the total loss of productivity and therefore for the costs that accompany it.In conclusion, there is a significant cost (direct and indirect) related to the treatment of AS in Greece. Functional impairment is the factor with the most significant cost impact. Biologic therapies that reduce functional impairment can be effective in reducing the cost of Axial SpA and improving the patient's quality of life and reducing stress in the health care system.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kougkas, Nikolaos
- Κούγκας, Νικόλαος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53174